Last update :
19/11/2024
Respiratory stimulant   Caffeine citrate  
injection
Oral solution
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Cafcit United States of America
Cafeina 25% Bioquim Argentina
Cafeina citrato Spain
Cafeina Fada Argentina
Cafeine citrate Biomed New Zealand
Cafeine Sterop Belgium
Cafeinnova Colombia
Caffeinospire Egypt
Cafirate India
Citrate de caféine Cooper France
Peyona oral y para perfusion Spain
Peyona oral/parenteral Germany, Romania, Turkey
References   injection   References : Caffeine citrate  
Type Publication
43 Journal Fraser BD, Berod T, Whitney HAK.
Stability of caffeine citrate injection in polypropylene syringes at room temperature.
Am J Health-Syst Pharm 1997 ; 54: 1106-1108.
318 Journal Donnelly RF, Tirona RG.
Stability of citrated caffeine injectable solution in glass vials.
Am J Hosp Pharm 1994 ; 51: 512-514.
691 Journal Nahata MC, Zingarelli JR, Durell DE.
Stability of caffeine citrate injection in intravenous admixtures and parenteral nutrition solutions.
J Clin Pharm Ther 1989 ; 14: 53-55.
1802 Journal Bell MS, Nolt DH.
Visual compatibility of doxapram hydrochloride with drugs commonly administered via a Y-site in the intensive care nursery.
Am J Health-Syst Pharm 2003 ; 60: 193-194.
2087 Journal Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
3379 Journal Fox L.M, Wilder A.G, Foushee J.A.
Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
Am J Health-Syst Pharm 2013 ;70:520-524.
3644 Manufacturer Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010
3976 Journal Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
4319 Journal Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4389 Journal Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.
Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévosimendan et la kétamine.
Pharmactuel 2019 ;52,4:206-213
4419 Journal Holt R.J, Siegert S.W.K, Krishna A.
Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection.
J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4543 Journal Senarathna G, Strunk T, Petrovski M, Batty K.
Physical compatibility of pentoxifylline and intravenous medications.
Archives of Disease in Childhood 2018 ;104:292–295.
4603 Journal Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4742 Journal Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.
4837 Journal De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page‑Sharp N, Moore B.R, Batty K.T.
Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings.
Eur J Clin Pharmacol 2024 ; 80:1079–1087.

  Mentions Légales